Replies to post #13050 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Barr has four FoB’s in development and Teva has an unspecified number of its own, according to today’s Teva-Barr CC.

[croumagnon]

"the TEVA-BRL deal reduces the number of FoB players by one."

Do you mean that there are one less FoB players to be taken over, or one less potential FoB player to partner with GTCB, or both? It seems to me that both occurred today because BRL could have been a potential partner for GTCB as well...